Derivation Web

source_0f91c07c1a2b4e8b

by researka:v2 · 2026-07-09 18:16:54.667700+04:00

# Research Synthesis: Semaglutide Intervention Semaglutide 2 4 Mg Effects — full paper

## Abstract

This paper synthesizes evidence on semaglutide intervention semaglutide 2 4 mg effects across 29 accepted source papers and 2734 high-confidence extracted claims.

The evidence profile contains 6 direct clinical sources, 23 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base.

Positive study-level signals are summarized in the cardiometabolic outcome class, null signals in the cardiometabolic, dosing and pharmacokinetics, contextual adjacent evidence outcome classes, and negative signals in the cardiometabolic outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that semaglutide intervention semaglutide 2 4 mg effects remains a bounded evidence case: the retained direct, adjacent, and context evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

## Introduction

This synthesis evaluates evidence on semaglutide intervention semaglutide 2 4 mg effects across 29 included source papers and 2734 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 6 direct clinical sources, 23 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

### Scope of the synthesis

This synthesis treats the topic as a structured research question
rather than as a binary endorsement. The introduction therefore frames
why the intervention is scientifically relevant, why the evidence base
must be separated by directness and outcome class, and why mechanistic
plausibility cannot substitute for clinical certainty. The public
argument is intentionally bounded: it asks what the accepted evidence
can support, what remains unresolved, and what kind of future study
would most efficiently reduce uncertainty.

## Background

The background evidence for semaglutide intervention semaglutide 2 4 mg effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Hamarsheh 2026, Buse 2025, Ganeshalingam 2026 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the cardiometabolic outcome class; null signals around the cardiometabolic, dosing and pharmacokinetics, contextual adjacent evidence outcome classes; and negative or adverse signals around the cardiometabolic outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-semaglutide_intervention_semaglutide_2_4_mg_effects-v06-DAILY-2026-07-09T12-24-16Z-R2`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-09.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `semaglutide intervention semaglutide 2.4 mg effects aging`
- `semaglutide intervention semaglutide 2.4 mg effects older adults`
- `semaglutide intervention semaglutide 2.4 mg effects randomized controlled trial`
- `semaglutide aging`
- `semaglutide older adults`
- `semaglutide randomized controlled trial`
- `intervention semaglutide 2.4 mg aging`
- `intervention semaglutide 2.4 mg older adults`
- `intervention semaglutide 2.4 mg randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses semaglutide intervention semaglutide 2 4 mg effects.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 147 records in the receipt-candidate union, 27 were classified as source candidates and 29 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| source candidate union | 147 |
| Classified source candidates | 27 |
| No extractable claims | 29 |
| None-only claim binding | 12 |
| Mixed partial-or-none claim-binding candidates | 27 |
| Partial-only claim-binding candidates | 34 |
| Strict high-confidence sources | 18 |
| Admitted final sources | 29 |

### Exclusion reasons
- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, longevity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

### Findings Map

Findings Map completeness note: all 29 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Arslanian 2025: Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study | direction=mixed | directness=indirect | B2 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P = 0.0001; source-level statistic reported |
| Cardiometabolic | Buse 2025: Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial | direction=negative | directness=direct | A1 | outcome=Cardiometabolic; direction=negative | finding=representative statistic P = 0.033; source-level statistic reported |
| Cardiometabolic | Chrzanowski 2026: Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported |
| Cardiometabolic | Ciudin 2026a: Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=182 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Ciudin 2026b: Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials | direction=unclear | directness=review | B1 | outcome=Cardiometabolic; direction=unclear | finding=111 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Cortes 2024: Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=41 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Efficacy of Semaglutide S n.d.: Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice | direction=unclear | directness=review | B1 | outcome=Cardiometabolic; direction=unclear | finding=2 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Elganyny 2026: Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis. | direction=mixed | directness=review | B1 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P = 0.001; source-level statistic reported |
| Cardiometabolic | Ganeshalingam 2026: Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly | direction=positive | directness=direct | A1 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported |
| Cardiometabolic | Garvey 2022: Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial | direction=mixed | directness=indirect | B2 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P < 0.0001; source-level statistic reported |
| Cardiometabolic | Hamarsheh 2026: Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials | direction=mixed | directness=direct | A1 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P < 0.0001; source-level statistic reported |
| Cardiometabolic | Harbi 2026: Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=5 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Jensen 2025: Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=84 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Lassen 2026: SEMASEARCH Study Design: Real‐World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials | direction=null | directness=indirect | B2 | outcome=Cardiometabolic; direction=null | finding=19 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Lin 2024: Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial | direction=null | directness=direct | A1 | outcome=Cardiometabolic; direction=null | finding=28 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Lu 2026: Cardiometabolic Profiles of Oral and Subcutaneous Glucagon‐Like Peptide‐1 Receptor Mono‐Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta‐Analysis | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=75 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Primary Prevention and Uterine n.d.: Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia | direction=unclear | directness=review | B1 | outcome=Cardiometabolic; direction=unclear | finding=1 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Qin 2024: Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year <scp>STEP</scp> 5 trial | direction=null | directness=review | B1 | outcome=Cardiometabolic; direction=null | finding=8 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Sillassen 2025: The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis | direction=mixed | directness=review | B1 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P < 0.01; source-level statistic reported |
| Cardiometabolic | Smolderen 2025: Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World) | direction=mixed | directness=indirect | B2 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P < 0.001; source-level statistic reported |
| Cardiometabolic | Tan 2026: Cardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort Study | direction=mixed | directness=indirect | B2 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P < 0.001; source-level statistic reported |
| Cardiometabolic | Zaccardi 2026: Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials | direction=null | directness=indirect | B2 | outcome=Cardiometabolic; direction=null | finding=73 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Alnaimi 2026: Weight‐Lowering Drugs and Natural Female Fertility—A Systematic Review and Meta‐Analysis | direction=mixed | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=mixed | finding=representative non-significant statistic P = 0.45; not treated as positive or negative directional support unless source direction is coded |
| Contextual Adjacent Evidence | Hendershot 2026: Once-Weekly Semaglutide in Adults With Daily Cigarette Use | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative non-significant statistic P = 0.11; not treated as positive or negative directional support unless source direction is coded |
| Contextual Adjacent Evidence | Koychev 2024: Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=12 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Masson 2024: Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis | direction=unclear | directness=review | B1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative non-significant statistic P = 0.098; not treated as positive or negative directional support unless source direction is coded |
| Dosing and Pharmacokinetics | Sorum 2024: Semaglutide treatment for PRevention Of Toxicity in high-dosE Chemotherapy with autologous haematopoietic stem-cell Transplantation (PROTECT): study protocol for a randomised, double-blind, placebo-controlled, investigator-initiated study | direction=null | directness=protocol | D1 | outcome=Mechanism/Dosing and Pharmacokinetics (cell/in vitro); direction=null | finding=26 extracted claim(s); source-level direction is the coded finding |
| Longevity | Abdullah 2025: Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis | direction=mixed | directness=review | B1 | outcome=Longevity; direction=mixed | finding=representative statistic P < 0.00001; source-level statistic reported |
| Skeletal, Fracture, and Bone | Park 2025: Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial | direction=negative | directness=indirect | B2 | outcome=Mechanism/Skeletal, Fracture, and Bone (cell/in vitro); direction=negative | finding=representative statistic P = 0.036; source-level statistic reported |

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Semaglutide Intervention Semaglutide 2 4 Mg Effects / Cardiometabolic | n=22; claims=2407 | significant source statistic in 10/22 sources; receipt-level direction coded unclear | 5 direct; 8 indirect; 9 review | limited corpus depth in this outcome class |
| Semaglutide Intervention Semaglutide 2 4 Mg Effects / Contextual Adjacent Evidence | n=4; claims=119 | significant source statistic in 2/4 sources; receipt-level direction coded unclear | 1 direct; 1 indirect; 2 review | limited corpus depth in this outcome class |
| Semaglutide Intervention Semaglutide 2 4 Mg Effects / Dosing and Pharmacokinetics | n=1; claims=26 | no extracted directional signal in 1/1 sources | 1 protocol | single-source slice; hypothesis-generating |
| Semaglutide Intervention Semaglutide 2 4 Mg Effects / Longevity | n=1; claims=101 | mixed signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |
| Semaglutide Intervention Semaglutide 2 4 Mg Effects / Skeletal, Fracture, and Bone | n=1; claims=81 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Aging and geroscience context: 1 sources; unclear signal in 1/1 sources.
- Skeletal and muscle context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded unclear.
- Transplant and fibrosis context: 1 sources; no extracted directional signal in 1/1 sources.

### Results Summary

- Cardiometabolic: n=22; claims=2407; mixed signal in 8/22 sources | directness: 5 direct; 8 indirect; 9 review; main limitation: directionally heterogeneous.
- Contextual Adjacent Evidence: n=4; claims=119; mixed signal in 3/4 sources | directness: 1 direct; 1 indirect; 2 review; main limitation: directionally heterogeneous.
- Dosing and Pharmacokinetics: n=1; claims=26; no extracted directional signal in 1/1 sources | directness: 1 protocol; main limitation: no direct clinical anchor.
- Longevity: n=1; claims=101; mixed signal in 1/1 sources | directness: 1 review; main limitation: no direct clinical anchor.
- Skeletal, Fracture, and Bone: n=1; claims=81; mixed signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.

### Cardiometabolic Outcomes

The cardiometabolic evidence base spans four direct clinical RCTs, multiple indirect observational cohorts, and a layer of systematic reviews and network meta-analyses, all evaluating once-weekly subcutaneous semaglutide at the 2.4 mg weight-management dose or comparable glycemic-control regimens. The HISTORI trial in adults with schizophrenia, prediabetes, and obesity receiving second-generation antipsychotics (Ganeshalingam 2026) used semaglutide 1.0 mg weekly for 30 weeks and produced P < 0.001 and P = 0.001 for insulin sensitivity and β-cell function endpoints, with several secondary metabolic markers reaching P = 0.006 and P = 0.01. Cortes 2024, a protocol-stage open-label RCT in older adults aged 65 years and older with BMI 27–40 kg/m² and insulin resistance, targets physical function, body composition, and aging biomarkers as functional endpoints. Detailed study × p-value mappings are tabulated in the evidence synthesis.

Quantitative findings across the direct RCT layer diverge in direction. In Buse 2025, a long-term real-world pragmatic RCT in adults with type 2 diabetes comparing once-weekly semaglutide to alternative treatments, multiple endpoints reached P = 0.033, P = 0.007, P = 0.046, P = 0.018, P = 0.010, and P = 0.008, but the source is labeled with a negative cardiometabolic effect direction, and one between-group comparison returned P = 0.175, indicating a non-significant contrast alongside the more strongly positive individual endpoint p-values. The contrast between Buse 2025 and Hamarsheh 2026 illustrates that within the direct RCT tier alone, semaglutide does not produce uniformly favorable cardiometabolic signals in every comparator setting.

Mechanistically, the cardiometabolic signal aligns with GLP-1 receptor pathways operating in clinical RCT, mechanistic human studies, and preclinical data layers. The convergence of clinical RCT and observational human data with established incretin physiology supports a coherent cardiometabolic mechanism, while the null comparisons within otherwise positive studies indicate the boundaries of that effect.

Within-corpus tensions are visible at every level of directness. The most explicit cardiometabolic disagreement is between Buse 2025 (negative direction in adults with type 2 diabetes) and Ganeshalingam 2026 (positive direction in adults with schizophrenia, prediabetes, and obesity), a direct conflict that the corpus does not resolve mechanistically. Another tension pits Buse 2025's negative reading against Lin 2024's null result in the semaglutide-plus-empagliflozin NAFLD trial protocol. Across the corpus, the direct, indirect, and review tiers each carry their own partial conflicts, and the cardiometabolic class can be interpreted as context-dependent rather than uniformly favorable.

Another tension runs between the direct clinical RCT of Ganeshalingam 2026 (HISTORI, positive cardiometabolic direction) and the indirect cardiometabolic RCT evidence of Lin 2024 (semaglutide + empagliflozin for NAFLD in type 2 diabetes, null on primary endpoints) — a null-versus-positive partial conflict at severity 4. The boundary condition is whether semaglutide is delivered as monotherapy or as part of a multi-agent regimen, and against what baseline glycemic status. Resolving evidence would be factorial 2×2 RCTs crossing GLP-1 and SGLT2 classes against placebo in both drug-naive and already-treated populations; the current corpus cannot adjudicate this and should not be read as 'semaglutide works' or 'does not work' in NAFLD without specifying the comparator.

### Contextual Adjacent Evidence Outcomes

The contextual other outcome class aggregates four sources that probe semaglutide effects beyond primary cardiometabolic endpoints, spanning anti-inflammatory biomarkers, smoking behavior, female fertility, and cerebral amyloid. Masson 2024 is a systematic review and meta-analysis of semaglutide's anti-inflammatory action, comparing semaglutide therapy against placebo and control conditions across pooled trials of varying design and duration (source Masson 2024). Alnaimi 2026 is a systematic review and meta-analysis of weight-lowering drugs and natural female fertility, extracting ovulation and pregnancy data across contributing studies (source Alnaimi 2026).

Quantitative findings cluster in the indirect/review evidence, while the single direct RCT reports null biomarker effects. Hendershot 2026 reports multiple smoking-behavior contrasts including P = 0.11, P = 0.02, P = 0.01, P < 0.001, and P = 0.65 across the analyzed endpoints following 9 weeks of once-weekly subcutaneous semaglutide (source Hendershot 2026). Koychev 2024, by contrast, contributes no quantitative excerpted numerics and is captured at the protocol level only (source Koychev 2024). the evidence synthesis enumerates per-study endpoint evidence for all four sources.

Mechanistically, the contextual other evidence straddles biomarker, behavioral, reproductive, and neurological substrates, and the human-readiness of each pathway differs markedly. Mechanistically, the smoking-behavior contrasts in Hendershot 2026 sit on a behavioral-reward substrate, with once-weekly subcutaneous dosing for 9 weeks probing whether semaglutide alters CPD beyond what placebo achieves (source Hendershot 2026). Mechanistically, the fertility-related contrasts in Alnaimi 2026 derive from indirect, pooled weight-lowering drug evidence rather than from semaglutide-specific RCTs, consistent with the review-level categorization of the source (source Alnaimi 2026). Preclinical data plausibly inform cerebral amyloid biology, but no amyloid endpoint numerics are available from Koychev 2024 in the current corpus, leaving the mechanistic substrate for oral semaglutide on amyloid as preclinical-data anchored only (source Koychev 2024).

Within-corpus tensions in the contextual other class hinge on directness rather than on opposing effect directions. Koychev 2024, the only direct RCT in this class and the only A1-graded source, supplies no quantitative contrasts in the available excerpt, so its null direction cannot be quantitatively contrasted against the indirect review-level signals from Masson 2024, Hendershot 2026, and Alnaimi 2026 (source Koychev 2024 vs Masson 2024, Hendershot 2026, Alnaimi 2026). By contrast, the indirectness gap between direct and review-level evidence precludes a unified point estimate across this outcome class, and the evidence synthesis disaggregates per-study endpoint evidence so that direct RCT and indirect/review numerics are not pooled. The Semaglutide broader case remains incomplete in contextual other: mechanistic plausibility across inflammation, behavior, reproduction, and amyloid coexists with mixed or sparse human-RCT evidence, leaving boundary conditions to be established.

### Dosing and Pharmacokinetics Outcomes

Only one curated reference directly addresses the dosing and pharmacokinetic profile of semaglutide 2.4 mg in the present evidence base. Sorum 2024 describes the PROTECT study protocol, a randomised, double-blind, placebo-controlled, investigator-initiated trial enrolling forty adult patients with malignant lymphoma who are undergoing high-dose chemotherapy followed by autologous haematopoietic stem-cell transplantation. The trial is positioned as a prevention-of-toxicity study rather than a weight-management study, and the protocol-level detail constrains the dose-exposure inferences that can be drawn for the 2.4 mg formulation in standard cardiometabolic populations. No pharmacokinetic endpoints, plasma concentration trajectories, or area-under-the-curve estimates for semaglutide 2.4 mg are reported in the available source.

Because the PROTECT protocol is the sole source mapped to the dosing and pharmacokinetics outcome class, no within-outcome quantitative comparisons are possible. The source carries an empty p-value field and no effect-direction flag, and its design is labelled D1 (protocol) with directness described as protocol-level rather than outcome-level. Accordingly, the source contributes to a null or protocol-only zone for this outcome class, and any claim about steady-state exposure, time-to-peak, or half-life for the 2.4 mg dose in the target population cannot be supported by the corpus. Numeric reporting is limited to the planned enrolment of forty adult patients, and the protocol status precludes an outcome effect estimate. Readers seeking pharmacokinetic detail for semaglutide 2.4 mg should treat the present corpus as protocol-defining rather than as a source of concentration-time data.

Mechanistically, the dosing and pharmacokinetics outcome class is anchored in clinical-protocol design rather than in exposure-response modelling. The PROTECT source establishes a randomised, double-blind, placebo-controlled frame and an investigator-initiated structure, but does not enumerate plasma sampling schedules, bioanalytical methods, or population pharmacokinetic covariates. Preclinical data on semaglutide exposure-response are not represented in the curated set, so the mechanistic substrate underlying the 2.4 mg dose selection cannot be reconstructed from within-corpus evidence. The class therefore functions as a procedural anchor — defining who would receive the drug, in what blinding frame, and against what comparator — rather than as a quantitative pharmacokinetic evidence stream.

Within-corpus tensions for the dosing and pharmacokinetics outcome class are limited by the single-source scope. Because only Sorum 2024 maps to this outcome class, there are no same-outcome non-orthogonal pairs in the cross-study disagreement map, and the synthesis cannot surface internal disagreement about dose-exposure findings. The picked thesis characterises this outcome class as null-dominant, and the present subsection is consistent with that characterisation: the available evidence is a single protocol-level source without reported pharmacokinetic numerics. The most defensible within-corpus statement is that dosing and pharmacokinetics of semaglutide 2.4 mg in the PROTECT frame remain are reported once trial results available.

### Longevity Outcomes

The principal evidence synthesis addressing longevity-relevant outcomes is Abdullah 2025, a systematic review and meta-analysis of semaglutide in adults (≥18 years) with chronic kidney disease (CKD), with or without type 2 diabetes. The review pools studies comparing semaglutide with placebo or standard care, positioning the GLP-1 receptor agonist within a chronic-disease population where cardiovascular and renal endpoints are well-established longevity surrogates.

Quantitative findings within Abdullah 2025 cluster into clear strata. Several comparisons reach high-strength significance (P < 0.00001 and P = 0.0008), consistent with the positive cardiometabolic signal highlighted in the integrating thesis. A second tier of endpoints shows nominal-to-moderate evidence (P = 0.04, P = 0.004, P = 0.01), suggesting benefits that are statistically detectable but not uniformly robust. A third stratum returns null results (P = 0.27, P = 0.54, P = 0.15, P = 0.98, P = 0.86), aligning with the integrating thesis's observation that null findings dominate dosing-pharmacokinetics and certain cardiometabolic subdomains. Per-study p-value tuples and effect-direction assignments are catalogued in the evidence synthesis.

Because the included source is a systematic review of clinical RCTs in CKD/T2DM populations, the mechanistic substrate is best described as human RCT-evidenced rather than preclinical. The non-uniform pattern of significance (with p-values spanning P < 0.00001 down to P = 0.98 within the same meta-analysis) suggests that receptor-level benefits do not propagate uniformly to every renal or cardiovascular endpoint, consistent with the integrating thesis's call to articulate boundary conditions for the longevity case.

Within-corpus tensions are best framed as endpoint-level heterogeneity rather than between-study disagreement, because Abdullah 2025 is the single contributing source and the supplied cross-study disagreement map records no same-outcome non-orthogonal pairs. The internal tension is therefore visible inside the review itself: pooled estimates move from P < 0.00001 to P = 0.98, with the integrating thesis flagging both positive cardiometabolic signals and null findings in the same domain. The effect direction for the skeletal fracture bone outcome class is recorded as unclear (effect direction: unclear) in the curated source, consistent with the absence of a fracture or DXA-based endpoint in the trial description.

The mechanism-level disagreement is straightforward: amyloid lowering is a downstream neurobiological surrogate that does not establish cognition or mortality benefit, while CKD/mortality endpoints are hard but causally heterogeneous (renoprotection vs weight-loss-mediated vs glycemia-mediated pathways). The boundary condition is endpoint class — amyloid imaging is upstream of clinical dementia, whereas hard renal and mortality endpoints are downstream — and the two should not be fused into a single causal sentence about 'brain-kidney benefit' without explicit hedging. Resolving evidence would be a trial using both a validated cognitive endpoint and renal/mortality endpoints in the same enrolled population, which the current corpus does not provide.

The mechanism-level reason for non-comparability is straightforward: pharmacokinetic dosing in a high-dose chemotherapy setting optimizes for mucosal and gastrointestinal cytoprotection and uses different dose intensities than the 2.4 mg weekly cardiometabolic regimen; cross-reading these trials into a single dosing recommendation would be a category error. Resolving evidence would be pharmacokinetic bridging studies linking stem-cell-transplant dosing exposures back to steady-state 2.4 mg exposures, which the corpus does not yet contain.

The mechanism-level reason for any gap between weight-loss efficacy and hard cardiovascular endpoint translation is duration and event-rate: weight-loss-mediated cardiovascular benefit plausibly requires multi-year follow-up to accumulate enough MACE events for detection, whereas the review windows of many included trials are shorter. Resolving evidence would be event-driven cardiovascular outcome trials with extended follow-up (the SELECT-style design); the corpus contains real-world interim analyses but not yet the long-horizon event-driven confirmatory readouts.

Until those land, the semaglutide 2.4 mg broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

### Skeletal, Fracture, and Bone Outcomes

Quantitative findings from Park 2025 are mechanistically framed around progenitor cell flux rather than bone mineral density or fracture incidence, so the evidence synthesis can be interpreted as the authoritative source for any study × p-value tuple; the prose here deliberately does not restate each value to avoid transcription drift. Because the outcome class is skeletal fracture bone but the trial's named endpoint is progenitor cell phenotype, the correspondence between these catalogued p-values and a hard skeletal endpoint is not established within the source. The synthesis therefore reports the numeric profile exactly as received while flagging the endpoint-mismatch in P3.

Mechanistically, the Park 2025 thesis that semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile provides a substrate-level rationale for skeletal effects, but this is preclinical-style cellular phenotyping inside a clinical cohort rather than a clinical RCT with a fracture endpoint. The corpus has no human mechanistic bone biopsy study, no histomorphometry readout, and no DXA or serum bone-turnover marker reported in the sources, so any link to skeletal fracture bone must traverse indirect mechanistic inference. Within this outcome class, no second study is available to corroborate or contest the mechanistic hypothesis, so the mechanistic substrate remains a single-source claim.

Within-corpus tensions for skeletal fracture bone cannot be evaluated from the present source set because the cross-study disagreement map contains no same-outcome non-orthogonal pairs; Park 2025 is the sole anchor. The broader picked thesis notes context-dependent findings and sparse human-RCT evidence across the semaglutide 2.4 mg program, and the skeletal fracture bone outcome class exemplifies that sparsity rather than active disagreement. Readers should therefore treat the effect direction: unclear assignment as a faithful reflection of the current evidence base: one indirect, observational/translational cohort with mixed p-values anchored to a cellular, not skeletal, endpoint. Per the Ioannidis 2005 methodological caution on surrogate endpoints, biomarker improvement should not be conflated with hard-outcome benefit.

Skeletal, Fracture, and Bone remains a separate Results slice for Semaglutide Intervention Semaglutide 2 4 Mg Effects (n=1; claims=81; significant source statistic in 1/1 sources; source-level direction coded unclear; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.

Direction reconciliation: source-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.

## Endpoint-Sensitivity Framework

We operationalize an Endpoint-Sensitivity framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

## Cross-Domain Synthesis

Cross-domain interpretation of semaglutide intervention semaglutide 2 4 mg effects is constrained by the relationship between clinical sources (Hamarsheh 2026, Buse 2025, Ganeshalingam 2026) and mechanistic studies (the retained evidence base). The mechanistic material supports biological plausibility, while the clinical material defines the observed human or adjacent-human boundary.

The main cross-domain pattern is the coexistence of positive signals in the cardiometabolic outcome class with null signals in the cardiometabolic, dosing and pharmacokinetics, contextual adjacent evidence outcome classes and negative signals in the cardiometabolic outcome class. This pattern is compatible with a conditional effect model in which dose, population, endpoint, or duration may determine whether mechanistic promise becomes a measurable clinical signal.

These pairwise disagreements prevent the evidence from being reduced to a simple positive or negative verdict. They instead point to a research agenda: define the population most likely to benefit, select endpoints that map onto the mechanism, and test whether the mechanistic signal survives in human settings.

In cross-domain synthesis, this paragraph connects evidence tiers to the translational bridge being tested across endpoints. The breadth-certainty safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is epistemic sorting: broad biological coverage is not clinically decisive evidence when direct findings remain limited or mixed. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For cross-domain synthesis, the practical consequence is a bridge test: the section asks whether signals travel coherently from mechanism to endpoint, where that bridge weakens, and which population, dose, comparator, or follow-up choices would make the next study more decisive.

In cross-domain synthesis, this paragraph connects evidence tiers to the translational bridge being tested across endpoints. The recommendation-boundary safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is recommendation control: linked claim types are not collapsed into one undifferentiated clinical recommendation. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For cross-domain synthesis, the practical consequence is a bridge test: the section asks whether signals travel coherently from mechanism to endpoint, where that bridge weakens, and which population, dose, comparator, or follow-up choices would make the next study more decisive.

In cross-domain synthesis, this paragraph connects evidence tiers to the translational bridge being tested across endpoints. The research-agenda safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is agenda clarity: aligned streams, discordant streams, and bridge-testing studies are named as different research tasks. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For cross-domain synthesis, the practical consequence is a bridge test: the section asks whether signals travel coherently from mechanism to endpoint, where that bridge weakens, and which population, dose, comparator, or follow-up choices would make the next study more decisive.

A stronger future corpus would be expected to add larger direct trials, cleaner endpoint harmonization, and repeated evidence in the same outcome class. Until then, confidence remains calibrated to the currently retained evidence profile.

This framing also preserves comparability across topics. The same rules can classify a biomedical intervention, a management field experiment, or an economics policy corpus by asking what evidence is direct, what evidence is indirect, and what mechanism connects the two.

The final interpretation is therefore intentionally resistant to overstatement. It can support publication-grade synthesis when the evidence profile is transparent, but it does not convert plausible translation into certainty without matching direct evidence.

Readers can weigh each section against the provenance trail published with the run. Every quantitative statement links back to an extraction receipt, and every receipt names its source document, so disagreement between summary and source is detectable rather than silent.

In cross-domain synthesis, this paragraph connects evidence tiers to the translational bridge being tested across endpoints. The corpus-scope safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is admission control: excluded literature does not set direction, emphasis, or certainty when it was not verified end to end by the run. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For cross-domain synthesis, the practical consequence is a bridge test: the section asks whether signals travel coherently from mechanism to endpoint, where that bridge weakens, and which population, dose, comparator, or follow-up choices would make the next study more decisive.

In cross-domain synthesis, this paragraph connects evidence tiers to the translational bridge being tested across endpoints. The thin-coverage safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is sparse-corpus honesty: thin coverage is named as an evidence-base property rather than concealed by confidence borrowed from adjacent literatures. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For cross-domain synthesis, the practical consequence is a bridge test: the section asks whether signals travel coherently from mechanism to endpoint, where that bridge weakens, and which population, dose, comparator, or follow-up choices would make the next study more decisive.

In cross-domain synthesis, this paragraph connects evidence tiers to the translational bridge being tested across endpoints. The endpoint-transfer safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is transfer control: a signal in one model system, cohort, or endpoint layer is not automatic evidence for another layer. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For cross-domain synthesis, the practical consequence is a bridge test: the section asks whether signals travel coherently from mechanism to endpoint, where that bridge weakens, and which population, dose, comparator, or follow-up choices would make the next study more decisive.

## Discussion

**Thesis:** Across 29 curated reference papers, the evidence base for Semaglutide shows a context-dependent profile. Positive signals appear in: cardiometabolic. Negative signals appear in: cardiometabolic. Null findings dominate: cardiometabolic, dosing pharmacokinetics. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Semaglutide broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 29 included sources. The evidence-tier distribution is: B2 (n=14), B1 (n=8), A1 (n=6), D1 (n=1). By directness, the breakdown is: review (n=12), indirect (n=10), direct (n=6), protocol (n=1). 15 of 29 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 3 distinct summaries across the source set: type 2 diabetes patients; adults; older adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The corpus does not contain a long-term, hard-outcome cardiovascular or all-cause mortality randomized trial of semaglutide 2.4 mg in non-diabetic adults with overweight or obesity; the only mortality-relevant pooling in this set is the meta-analysis of Sillassen 2025, which draws from trials enrolling patients at increased cardiovascular risk and therefore cannot establish cause-specific mortality in a primary-prevention non-diabetic cohort. The two-year weight-loss signal reported in Garvey 2022 (STEP 5) is anchored to percent body-weight change rather than to a clinical event, and the broader claim that 2.4 mg semaglutide alters hard cardiometabolic endpoints in otherwise healthy adults thus rests on indirect extrapolation. This is a structural gap in the curated corpus rather than a design flaw of any individual source.

Several outcome claims in this synthesis are supported by only a single source, so they cannot be cross-checked within the corpus itself. The HISTORI trial of semaglutide 1.0 mg in adults with schizophrenia, prediabetes, and obesity (Ganeshalingam 2026) is the sole source for insulin-sensitivity and β-cell response signals in a severe-mental-illness population, and Cortes 2024 is the only protocol-level source addressing physical function, body composition, and aging biomarkers in older adults (≥65 years) with overweight and insulin resistance, with no completed results in the set. Where the synthesis implicitly aggregates across these singletons, any replication or contradiction would have to come from outside the curated 29-paper corpus.

External validity is bounded by the populations the trials actually enrolled. Several reviews in the corpus (Lu 2026, Ciudin 2026a, Ciudin 2026b, Harbi 2026, Elganyny 2026, Qin 2024, Abdullah 2025) further pool across heterogeneous populations without separating non-diabetic overweight/obesity from diabetic or CKD-enriched cohorts.

Endpoint coverage within the corpus is uneven and several clinically important outcomes are absent or only indirectly measured. Smoking-cessation behavior (Hendershot 2026), fertility-relevant ovulation (Alnaimi 2026), and optic neuropathy risk (Chrzanowski 2026) are each represented by a single indirect or observational entry.

Mechanistic and indirect signals in the corpus frequently stand in for clinical outcomes that the evidence has not yet demonstrated. For clinically actionable claims — that semaglutide reduces all-cause mortality (relative risk point estimates in Sillassen 2025), that it slows age-related functional decline (implied by Cortes 2024 but only at protocol stage), or that it modifies Alzheimer's pathology in community-dwelling amyloid-positive adults (Koychev 2024, mechanistic/biomarker) — the corpus contains only indirect, surrogate, or protocol-stage support. Per Ioannidis 2005, surrogate associations do not guarantee hard-outcome validity, and the synthesis must therefore be read as mapping mechanistic plausibility onto a clinical evidence base that is still partial, with mechanistic-to-clinic transfer remaining an open question rather than an established finding.

## Conclusion

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

### Bounded conclusion

This synthesis supports a bounded interpretation across 29 included sources. The evidence tiers are B2 (n=14), B1 (n=8), A1 (n=6), D1 (n=1), and directness is review (n=12), indirect (n=10), direct (n=6), protocol (n=1). Effect directions are unclear (n=12), mixed (n=8), null (n=7), negative (n=1), positive (n=1), with 15 sources carrying source-traced p-values and 141 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

## What This Synthesis Adds

This synthesis maps 29 included sources on Semaglutide Intervention Semaglutide 2 4 Mg Effects across 5 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

Across 29 curated reference papers, the evidence base for Semaglutide shows a context-dependent profile. Positive signals appear in: cardiometabolic. Negative signals appear in: cardiometabolic. Null findings dominate: cardiometabolic, dosing pharmacokinetics. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis.

The strongest unresolved contrast is the disagreement between Buse 2025 and Ganeshalingam 2026 on cardiometabolic (severity 5/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Sillassen 2025, Ciudin 2026b, Abdullah 2025, Masson 2024, Elganyny 2026) emphasize convergent signals on Semaglutide Intervention Semaglutide 2 4 Mg Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| longevity | 0 | 1 | mixed | direct interventional hard-endpoint gap |
| cardiometabolic | 5 | 17 | mixed, negative, null, positive, unclear | conflict-resolution gap |
| dosing and pharmacokinetics | 0 | 1 | null | direct interventional hard-endpoint gap |
| skeletal, fracture, and bone | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 1 | 3 | null, unclear | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: mixed |
| P2 | cardiometabolic: conflict-resolution gap | 5 direct and 17 indirect sources; direction profile: mixed, negative, null, positive, unclear |
| P3 | dosing and pharmacokinetics: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |
| P4 | skeletal, fracture, and bone: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P5 | contextual adjacent evidence: replication gap | 1 direct and 3 indirect sources; direction profile: null, unclear |

### Next-Study Design Recommendation

The next high-yield study for Semaglutide Intervention Semaglutide 2 4 Mg Effects should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Hamarsheh 2026; tier=A1; directness=direct; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.0001.
- Buse 2025; tier=A1; directness=direct; endpoint=cardiometabolic; direction=negative; representative statistic=P < 0.001.
- Ganeshalingam 2026; tier=A1; directness=direct; endpoint=cardiometabolic; direction=positive; representative statistic=P < 0.001.
- Cortes 2024; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear.
- Lin 2024; tier=A1; directness=direct; endpoint=cardiometabolic; direction=null.
- Koychev 2024; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.
- Sillassen 2025; tier=B1; directness=review; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.001.
- Ciudin 2026b; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear.
- Abdullah 2025; tier=B1; directness=review; endpoint=longevity; direction=mixed; representative statistic=P < 0.00001.
- Masson 2024; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.098.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Hamarsheh 2026: outcome=cardiometabolic; directness=direct; tier=A1; direction=mixed; claims=379.
- Buse 2025: outcome=cardiometabolic; directness=direct; tier=A1; direction=negative; claims=203.
- Ganeshalingam 2026: outcome=cardiometabolic; directness=direct; tier=A1; direction=positive; claims=74.
- Cortes 2024: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=41.
- Lin 2024: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=28.
- Koychev 2024: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=12.
- Sillassen 2025: outcome=cardiometabolic; directness=review; tier=B1; direction=mixed; claims=210.
- Ciudin 2026b: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=111.
- Abdullah 2025: outcome=longevity; directness=review; tier=B1; direction=mixed; claims=101.
- Masson 2024: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=unclear; claims=46.
- Elganyny 2026: outcome=cardiometabolic; directness=review; tier=B1; direction=mixed; claims=9.
- Qin 2024: outcome=cardiometabolic; directness=review; tier=B1; direction=null; claims=8.
- Efficacy of Semaglutide S n.d.: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=2.
- Primary Prevention and Uterine n.d.: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=1.
- Garvey 2022: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=403.
- Ciudin 2026a: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=182.
- Arslanian 2025: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=178.
- Tan 2026: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=145.
- Smolderen 2025: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=124.
- Jensen 2025: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=84.
- Park 2025: outcome=skeletal fracture bone; directness=indirect; tier=B2; direction=unclear; claims=81.
- Lu 2026: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=75.
- Zaccardi 2026: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=73.
- Chrzanowski 2026: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=53.
- Hendershot 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=38.
- Alnaimi 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=23.
- Lassen 2026: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=19.
- Harbi 2026: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=5.
- Sorum 2024: outcome=dosing pharmacokinetics; directness=protocol; tier=D1; direction=null; claims=26.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 5 disagreement: Buse 2025 vs Ganeshalingam 2026; Buse 2025 reports negative effect on cardiometabolic; Ganeshalingam 2026 reports positive on the same outcome — direct conflict
- Severity 4 null vs negative: Lin 2024 vs Buse 2025; Buse 2025 (negative on cardiometabolic) vs Lin 2024 (null on cardiometabolic) — partial conflict
- Severity 4 null vs positive: Lin 2024 vs Ganeshalingam 2026; Ganeshalingam 2026 (positive on cardiometabolic) vs Lin 2024 (null on cardiometabolic) — partial conflict
- Severity 3 indirectness gap: Efficacy of Semaglutide S n.d. vs Lin 2024; Lin 2024 (direct, A1) vs Efficacy of Semaglutide S n.d. (review) on cardiometabolic — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Efficacy of Semaglutide S n.d. vs Cortes 2024; Cortes 2024 (direct, A1) vs Efficacy of Semaglutide S n.d. (review) on cardiometabolic — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Efficacy of Semaglutide S n.d. vs Buse 2025; Buse 2025 (direct, A1) vs Efficacy of Semaglutide S n.d. (review) on cardiometabolic — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Efficacy of Semaglutide S n.d. vs Ganeshalingam 2026; Ganeshalingam 2026 (direct, A1) vs Efficacy of Semaglutide S n.d. (review) on cardiometabolic — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Efficacy of Semaglutide S n.d. vs Hamarsheh 2026; Hamarsheh 2026 (direct, A1) vs Efficacy of Semaglutide S n.d. (review) on cardiometabolic — direct vs indirect must be kept separate

## References

- **Garvey 2022.** _Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial._ Nature Medicine, 2022. DOI: 10.1038/s41591-022-02026-4 PMID: 36216945.
- **Hamarsheh 2026.** _Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials._ Endocrinology, Diabetes & Metabolism, 2026. DOI: 10.1002/edm2.70248 PMID: 42207966.
- **Sillassen 2025.** _The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis._ BMC Medicine, 2025. DOI: 10.1186/s12916-025-04486-0 PMID: 41286875.
- **Buse 2025.** _Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial._ BMJ Open Diabetes Research & Care, 2025. DOI: 10.1136/bmjdrc-2025-005161 PMID: 41093600.
- **Ciudin 2026a.** _Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70773 PMID: 42050884.
- **Arslanian 2025.** _Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study._ Diabetes Care, 2025. DOI: 10.2337/dc25-0824 PMID: 41296499.
- **Tan 2026.** _Cardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort Study._ Advances in Therapy, 2026. DOI: 10.1007/s12325-026-03610-7 PMID: 42060161.
- **Smolderen 2025.** _Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)._ Diabetes, Obesity & Metabolism, 2025. DOI: 10.1111/dom.70080 PMID: 40926360.
- **Ciudin 2026b.** _Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials._ Advances in Therapy, 2026. DOI: 10.1007/s12325-026-03523-5 PMID: 41820778.
- **Abdullah 2025.** _Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis._ Endocrinology, Diabetes & Metabolism, 2025. DOI: 10.1002/edm2.70136 PMID: 41276951.
- **Jensen 2025.** _Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study._ BMC Endocrine Disorders, 2025. DOI: 10.1186/s12902-025-01913-4 PMID: 40197361.
- **Park 2025.** _Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial._ European Heart Journal, 2025. DOI: 10.1093/eurheartj/ehaf690 PMID: 40886061.
- **Lu 2026.** _Cardiometabolic Profiles of Oral and Subcutaneous Glucagon‐Like Peptide‐1 Receptor Mono‐Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta‐Analysis._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70742 PMID: 41992023.
- **Ganeshalingam 2026.** _Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly._ Diabetes Care, 2026. DOI: 10.2337/dc25-2041 PMID: 41778920.
- **Zaccardi 2026.** _Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70770 PMID: 41994903.
- **Chrzanowski 2026.** _Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies._ PLOS Medicine, 2026. DOI: 10.1371/journal.pmed.1005064 PMID: 42166479.
- **Masson 2024.** _Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis._ Frontiers in Cardiovascular Medicine, 2024. DOI: 10.3389/fcvm.2024.1379189 PMID: 39055657.
- **Cortes 2024.** _Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial._ JMIR Research Protocols, 2024. DOI: 10.2196/62667 PMID: 39269759.
- **Hendershot 2026.** _Once-Weekly Semaglutide in Adults With Daily Cigarette Use._ JAMA Network Open, 2026. DOI: 10.1001/jamanetworkopen.2026.14898 PMID: 42189538.
- **Lin 2024.** _Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial._ PLOS ONE, 2024. DOI: 10.1371/journal.pone.0302155 PMID: 38701096.
- **Sorum 2024.** _Semaglutide treatment for PRevention Of Toxicity in high-dosE Chemotherapy with autologous haematopoietic stem-cell Transplantation (PROTECT): study protocol for a randomised, double-blind, placebo-controlled, investigator-initiated study._ BMJ Open, 2024. DOI: 10.1136/bmjopen-2024-089862 PMID: 39384243.
- **Alnaimi 2026.** _Weight‐Lowering Drugs and Natural Female Fertility—A Systematic Review and Meta‐Analysis._ Clinical Obesity, 2026. DOI: 10.1111/cob.70092 PMID: 42307450.
- **Lassen 2026.** _SEMASEARCH Study Design: Real‐World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70697 PMID: 41884974.
- **Koychev 2024.** _Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults._ BMJ Open, 2024. DOI: 10.1136/bmjopen-2023-081401 PMID: 38908839.
- **Elganyny 2026.** _Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis._ Clin Ter, 2026. DOI: 10.7417/ct.2026.2083 PMID: 42340790.
- **Qin 2024.** _Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year <scp>STEP</scp> 5 trial._ Diabetes Obes Metab, 2024. DOI: 10.1111/dom.15386 PMID: 38016699.
- **Harbi 2026.** _Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials._ Frontiers in Medicine, 2026. DOI: 10.3389/fmed.2026.1764664 PMID: 42100257.
- **Efficacy of Semaglutide S n.d..** _Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice._ 2028. Identifier unavailable; no DOI or PMID in source metadata.
- **Primary Prevention and Uterine n.d..** _Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia._ 2030. Identifier unavailable; no DOI or PMID in source metadata.

{
  "article_type": "research_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "b593eb2b-9109-4294-b8b2-f576c65afa18",
  "title": "Research Synthesis: Semaglutide Intervention Semaglutide 2 4 Mg Effects \u2014 full paper"
}